Published in ACS Chem Biol on March 05, 2012
Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol (2014) 1.41
Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol (2014) 1.35
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem Biol (2012) 1.16
Myotonic dystrophy. Neurol Clin (2014) 1.08
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun (2013) 1.01
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res (2014) 1.00
Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactions. Angew Chem Int Ed Engl (2013) 0.98
Reducing levels of toxic RNA with small molecules. ACS Chem Biol (2013) 0.96
A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. ACS Chem Biol (2013) 0.93
Probing a 2-aminobenzimidazole library for binding to RNA internal loops via two-dimensional combinatorial screening. ACS Chem Biol (2012) 0.93
Functional Rescue of F508del-CFTR Using Small Molecule Correctors. Front Pharmacol (2012) 0.90
Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules. Nucleic Acids Res (2013) 0.88
Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1. J Med Chem (2013) 0.88
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
Expanded complexity of unstable repeat diseases. Biofactors (2012) 0.87
Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr Opin Neurol (2012) 0.86
Methods to enable the design of bioactive small molecules targeting RNA. Org Biomol Chem (2014) 0.86
Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorg Med Chem Lett (2014) 0.85
Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res (2014) 0.85
Small-molecule-mediated cleavage of RNA in living cells. Angew Chem Int Ed Engl (2012) 0.84
Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor. Chem Commun (Camb) (2014) 0.84
Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol (2014) 0.82
Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1. RNA Biol (2014) 0.81
Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. ACS Chem Biol (2016) 0.81
Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling. ACS Chem Biol (2015) 0.81
Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts. Drug Discov Today (2013) 0.80
Modifications to toxic CUG RNAs induce structural stability, rescue mis-splicing in a myotonic dystrophy cell model and reduce toxicity in a myotonic dystrophy zebrafish model. Nucleic Acids Res (2014) 0.80
Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther (2013) 0.80
RNA Structures as Mediators of Neurological Diseases and as Drug Targets. Neuron (2015) 0.79
Structure based approaches for targeting non-coding RNAs with small molecules. Curr Opin Struct Biol (2015) 0.79
Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets? Neurodegener Dis Manag (2014) 0.78
Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models. J Med Chem (2015) 0.78
Influence of dimethylsulfoxide on RNA structure and ligand binding. Anal Chem (2013) 0.78
TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet (2014) 0.77
Small molecules that target the toxic RNA in myotonic dystrophy type 2. ChemMedChem (2014) 0.77
HIV-1 drug discovery: targeting folded RNA structures with branched peptides. Org Biomol Chem (2015) 0.77
Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10. Nat Commun (2016) 0.76
Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nat Chem Biol (2016) 0.76
Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I. J Biol Chem (2016) 0.76
Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev (2017) 0.75
Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. Annu Rev Pharmacol Toxicol (2015) 0.75
Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA. Bioorg Med Chem (2016) 0.75
Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1. Bioorg Med Chem Lett (2016) 0.75
Computational investigation of RNA CUG repeats responsible for myotonic dystrophy 1. J Chem Theory Comput (2015) 0.75
An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TAR-Dependent Transcription. ACS Chem Biol (2016) 0.75
Defining RNA motif-aminoglycoside interactions via two-dimensional combinatorial screening and structure-activity relationships through sequencing. Bioorg Med Chem (2013) 0.75
The Emerging Role of RNA as a Therapeutic Target for Small Molecules. Cell Chem Biol (2016) 0.75
Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR. Medchemcomm (2017) 0.75
RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The sequence of the human genome. Science (2001) 101.55
Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science (1998) 6.67
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol (1995) 4.04
Muscleblind proteins regulate alternative splicing. EMBO J (2004) 4.01
High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS One (2007) 3.84
Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol (2001) 3.39
Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet (2002) 3.34
Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet (2001) 3.27
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in E. coli. Nat Genet (1995) 2.99
RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem (2000) 2.65
MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA (2007) 2.58
MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene (2006) 2.47
Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 2.43
Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci (2005) 2.31
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res (2001) 1.97
Two-dimensional combinatorial screening identifies specific aminoglycoside-RNA internal loop partners. J Am Chem Soc (2008) 1.84
A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol (2007) 1.83
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem Biol (2009) 1.83
An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat Biotechnol (2001) 1.77
Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc (2009) 1.54
RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord (2004) 1.40
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Eur J Histochem (2006) 1.15
The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies. Chembiochem (2010) 1.13
Structure-activity relationships through sequencing (StARTS) defines optimal and suboptimal RNA motif targets for small molecules. Angew Chem Int Ed Engl (2010) 1.11
Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J Am Chem Soc (2011) 1.09
Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3' untranslated region transcripts. EMBO Rep (2005) 1.00
Non-coding RNA transcripts: sensors of neuronal stress, modulators of synaptic plasticity, and agents of change in the onset of Alzheimer's disease. Neurosci Lett (2009) 0.96
Expression of MBNL and CELF mRNA transcripts in muscles with myotonic dystrophy. Neuromuscul Disord (2007) 0.94
Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res (2008) 0.92
In situ hybridization analysis of Dmpk mRNA in adult mouse tissues. Neuromuscul Disord (2004) 0.84
Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A (2004) 10.35
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet (2006) 4.35
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 3.21
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Gene expression profile of aging in human muscle. Physiol Genomics (2003) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol (2006) 2.02
Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol (2004) 2.00
RNA-dominant diseases. Hum Mol Genet (2006) 2.00
Recent advances in developing small molecules targeting RNA. ACS Chem Biol (2012) 1.97
Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol (2007) 1.91
Hybridization-based unquenching of DNA hairpins on au surfaces: prototypical "molecular beacon" biosensors. J Am Chem Soc (2003) 1.88
A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol (2007) 1.83
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2006) 1.83
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem Biol (2009) 1.83
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
A superfolding Spinach2 reveals the dynamic nature of trinucleotide repeat-containing RNA. Nat Methods (2013) 1.62
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep (2013) 1.56
Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science (2014) 1.54
Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc (2009) 1.54
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 1.46
5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol (2004) 1.46
Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics (2002) 1.44
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
Tools for glycomics: mapping interactions of carbohydrates in biological systems. Chembiochem (2004) 1.32
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve (2007) 1.23
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing. Proc Natl Acad Sci U S A (2002) 1.21
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
A mannan binding lectin is involved in cell-cell attachment in a toxic strain of Microcystis aeruginosa. Mol Microbiol (2006) 1.16
Structure-activity relationships through sequencing (StARTS) defines optimal and suboptimal RNA motif targets for small molecules. Angew Chem Int Ed Engl (2010) 1.11
Myotonic syndromes. Curr Opin Neurol (2002) 1.11
Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther (2011) 1.10
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet (2007) 1.09
Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J Am Chem Soc (2011) 1.09
If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08
Reduced amount of mitochondrial DNA in aged human muscle. J Appl Physiol (1985) (2002) 1.07
Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology (2004) 1.06
Two-dimensional combinatorial screening identifies specific 6'-acylated kanamycin A- and 6'-acylated neamine-RNA hairpin interactions. Biochemistry (2008) 1.06
Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem Biol (2012) 1.05
Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve (2007) 1.03
Defining the mode, energetics and specificity with which a macrocyclic hexaoxazole binds to human telomeric G-quadruplex DNA. Nucleic Acids Res (2007) 1.02
Properties of Nat4, an N(alpha)-acetyltransferase of Saccharomyces cerevisiae that modifies N termini of histones H2A and H4. Mol Cell Biol (2009) 1.02
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun (2013) 1.01
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther (2012) 1.00
Two-dimensional combinatorial screening and the RNA Privileged Space Predictor program efficiently identify aminoglycoside-RNA hairpin loop interactions. Nucleic Acids Res (2009) 1.00
Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 × 1 nucleotide UU internal loop conformations. Biochemistry (2011) 1.00
Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem (2012) 0.99
Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactions. Angew Chem Int Ed Engl (2013) 0.98
Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97
Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations. Nat Commun (2012) 0.97
Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab (2009) 0.96
Reducing levels of toxic RNA with small molecules. ACS Chem Biol (2013) 0.96
Two-dimensional combinatorial screening of a bacterial rRNA A-site-like motif library: defining privileged asymmetric internal loops that bind aminoglycosides. Biochemistry (2010) 0.95
NMR spectroscopy and molecular dynamics simulation of r(CCGCUGCGG)₂ reveal a dynamic UU internal loop found in myotonic dystrophy type 1. Biochemistry (2011) 0.95
Small molecule microarrays of RNA-focused peptoids help identify inhibitors of a pathogenic group I intron. ACS Chem Biol (2009) 0.94
Probing a 2-aminobenzimidazole library for binding to RNA internal loops via two-dimensional combinatorial screening. ACS Chem Biol (2012) 0.93
Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res (2008) 0.92
Targeting human telomeric G-quadruplex DNA with oxazole-containing macrocyclic compounds. Biochimie (2008) 0.91
The role of RNA and RNA processing in neurodegeneration. J Neurosci (2005) 0.88
Molecular recognition of 6'-N-5-hexynoate kanamycin A and RNA 1x1 internal loops containing CA mismatches. Biochemistry (2011) 0.88
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
Macrocyclic hexaoxazoles: Influence of aminoalkyl substituents on RNA and DNA G-quadruplex stabilization and cytotoxicity. Bioorg Med Chem Lett (2010) 0.87
Using modularly assembled ligands to bind RNA internal loops separated by different distances. Chembiochem (2011) 0.87
A G-quadruplex stabilizer induces M-phase cell cycle arrest. J Biol Chem (2009) 0.87
A simple ligation-based method to increase the information density in sequencing reactions used to deconvolute nucleic acid selections. RNA (2007) 0.87
A toxic RNA catalyzes the in cellulo synthesis of its own inhibitor. Angew Chem Int Ed Engl (2014) 0.87
Scaled-down genetic analysis of myotonic dystrophy type 1 and type 2. Neuromuscul Disord (2009) 0.85
A crystal structure of a model of the repeating r(CGG) transcript found in fragile X syndrome. Chembiochem (2011) 0.85